Submitted:
22 May 2026
Posted:
26 May 2026
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Subjects and Methods
2.1. Study Design
2.2. Subjects’ Data Collection
2.3. Ocular Assessment
2.3.1. Instrumental Examinations
2.3.2. National Eye Institute Visual Function Questionnaire (NEI-VFQ 25)
2.4. Dietary Assessment
Mediterranean Diet Score
2.5. Statistical Analysis
Sample Size Calculation
3. Results
3.1. Overall Study Population
3.2. Groups with and Without Diabetic Retinopathy
3.2.1. Demographic, Clinical and Biochemical Characteristics
3.2.2. Vision-Related Quality of Life
3.2.3. Dietary Intake and Mediterranean Diet Adherence
3.2.4. Association Between Legume Consumption and Diabetic Retinopathy
3.2.5. Correlation Analyses
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119. [Google Scholar] [CrossRef]
- Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022, 45, S17–S38. [CrossRef]
- Monami, M.; Cignarelli, A.; Pinto, S.; D’onofrio, L.; Milluzzo, A.; Miccoli, R.; Penno, G.; Mannucci, E. Alpha-Tocopherol and Contrast-Induced Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Int. J. Vitam. Nutr. Res. 2021, 91. [Google Scholar] [CrossRef]
- Wong, T.Y.; Cheung, C.M.G.; Larsen, M.; Sharma, S.; Simó, R. Diabetic Retinopathy. Nat. Rev. Dis. Prim. 2016, 2, 16012. [Google Scholar] [CrossRef]
- Knudsen, L.L.; Lervang, H.-H.; Lundbye-Christensen, S.; Gorst-Rasmussen, A. The North Jutland County Diabetic Retinopathy Study: Population Characteristics. Br. J. Ophthalmol. 2006, 90, 1404–1409. [Google Scholar] [CrossRef]
- Giuffrè, G.; Lodato, G.; Dardanoni, G. Prevalence and Risk Factors of Diabetic Retinopathy in Adult and Elderly Subjects: The Casteldaccia Eye Study. Graefe’s Arch. Clin. Exp. Ophthalmol. 2004, 242, 535–540. [Google Scholar] [CrossRef] [PubMed]
- Resnikoff, S.; Keys, T. Future Trends in Global Blindness. Indian J. Ophthalmol. 2012, 60, 387. [Google Scholar] [CrossRef] [PubMed]
- Jampol, L.M.; Glassman, A.R.; Sun, J. Evaluation and Care of Patients with Diabetic Retinopathy. N. Engl. J. Med. 2020, 382, 1629–1637. [Google Scholar] [CrossRef] [PubMed]
- Antonetti, D.A.; Klein, R.; Gardner, T.W. Diabetic Retinopathy. N. Engl. J. Med. 2012, 366, 1227–1239. [Google Scholar] [CrossRef]
- Sabanayagam, C.; Yip, W.; Ting, D.S.W.; Tan, G.; Wong, T.Y. Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. Ophthalmic Epidemiol. 2016, 23, 209–222. [Google Scholar] [CrossRef]
- MILLUZZO, A.; BARCHITTA, M.; MAUGERI, A.; AGODI, A.; SCIACCA, L. Body Mass Index Is Related to Short Term Retinal Worsening in Type 2 Diabetes Patients Treated with Anticancer Drugs. Minerva Endocrinol. 2022. [Google Scholar] [CrossRef]
- Tumminia, A.; Milluzzo, A.; Carrubba, N.; Vinciguerra, F.; Baratta, R.; Frittitta, L. Excessive Generalized and Visceral Adiposity Is Associated with a Higher Prevalence of Diabetic Retinopathy in Caucasian Patients with Type 2 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2024, 34, 763–770. [Google Scholar] [CrossRef]
- Milluzzo, A.; Manuella, L.; Frittitta, L.; Sciacca, L. Cancer Drugs and Diabetic Retinopathy: A Dangerous, Underestimated Association. Metab. Target Organ Damage 2024, 4. [Google Scholar] [CrossRef]
- Milluzzo, A.; Tumminia, A.; Vella, V.; Gianì, F.; Manzella, L.; Frittitta, L.; Belfiore, A.; Vigneri, R.; Sciacca, L. Short-Term Adverse Effects of Anticancer Drugs in Patients with Type 2 Diabetes. J. Chemother. 2019, 31. [Google Scholar] [CrossRef] [PubMed]
- Bhatwadekar, A.D.; Shughoury, A.; Belamkar, A.; Ciulla, T.A. Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. Genes 2021, 12, 1200. [Google Scholar] [CrossRef]
- Han, J.; Lando, L.; Skowronska-Krawczyk, D.; Chao, D.L. Genetics of Diabetic Retinopathy. Curr. Diab. Rep. 2019, 19, 67. [Google Scholar] [CrossRef]
- Leslie, R.D.G.; Pyke, D.A. Diabetic Retinopathy in Identical Twins. Diabetes 1982, 31, 19–21. [Google Scholar] [CrossRef] [PubMed]
- Khullar, M.; Cheema, B.S.; Raut, S.K. Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes. Front. Endocrinol. . 2017, 8. [Google Scholar] [CrossRef]
- Ling, C.; Groop, L. Epigenetics: A Molecular Link Between Environmental Factors and Type 2 Diabetes. Diabetes 2009, 58, 2718–2725. [Google Scholar] [CrossRef] [PubMed]
- Gilbert, E.R.; Liu, D. Epigenetics: The Missing Link to Understanding β-Cell Dysfunction in the Pathogenesis of Type 2 Diabetes. Epigenetics 2012, 7, 841–852. [Google Scholar] [CrossRef]
- Milluzzo, A.; Maugeri, A.; Barchitta, M.; Sciacca, L.; Agodi, A. Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review. Int. J. Mol. Sci. 2021, 22. [Google Scholar] [CrossRef]
- Aro, A.; Kauppinen, A.; Summanen, P.; Kivinen, N.; Selander, T.; Kinnunen, K.; Tuomilehto, J.; Keinänen-Kiukaanniemi, S.; Lindström, J.; Uusitupa, M.; et al. Life Style Intervention Improves Retinopathy Status—The Finnish Diabetes Prevention Study. Nutrients 2019, 11, 1691. [Google Scholar] [CrossRef]
- Tyrberg, M.; Nyström, L.; Arnqvist, H.J.; Bolinder, J.; Gudbjörnsdottir, S.; Landin-Olsson, M.; Eriksson, J.W.; Svensson, M.K. Overweight, Hyperglycemia and Tobacco Use Are Modifiable Risk Factors for Onset of Retinopathy 9 and 17 Years after the Diagnosis of Diabetes—A Retrospective Observational Nation-Wide Cohort Study. Diabetes Res. Clin. Pract. 2017, 133, 21–29. [Google Scholar] [CrossRef]
- Bryl, A.; Mrugacz, M.; Falkowski, M.; Zorena, K. The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature. Nutrients 2022, 14, 1252. [Google Scholar] [CrossRef] [PubMed]
- Milluzzo, A.; Barchitta, M.; Maugeri, A.; Magnano San Lio, R.; Favara, G.; Mazzone, M.G.; Sciacca, L.; Agodi, A. Do Nutrients and Nutraceuticals Play a Role in Diabetic Retinopathy? A Systematic Review. Nutrients 2022, 14, 4430. [Google Scholar] [CrossRef]
- Testa, R.; Bonfigli, A.R.; Prattichizzo, F.; La Sala, L.; De Nigris, V.; Ceriello, A. The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients 2017, 9, 437. [Google Scholar] [CrossRef]
- Shi, C.; Wang, P.; Airen, S.; Brown, C.; Liu, Z.; Townsend, J.H.; Wang, J.; Jiang, H. Nutritional and Medical Food Therapies for Diabetic Retinopathy. Eye Vis. 2020, 7, 33. [Google Scholar] [CrossRef]
- Valle, M.S.; Russo, C.; Malaguarnera, L. Protective Role of Vitamin D against Oxidative Stress in Diabetic Retinopathy. Diabetes. Metab. Res. Rev. 2021, 37. [Google Scholar] [CrossRef] [PubMed]
- Valero-Vello, M.; Peris-Martínez, C.; García-Medina, J.J.; Sanz-González, S.M.; Ramírez, A.I.; Fernández-Albarral, J.A.; Galarreta-Mira, D.; Zanón-Moreno, V.; Casaroli-Marano, R.P.; Pinazo-Duran, M.D. Searching for the Antioxidant, Anti-Inflammatory, and Neuroprotective Potential of Natural Food and Nutritional Supplements for Ocular Health in the Mediterranean Population. Foods 2021, 10, 1231. [Google Scholar] [CrossRef]
- Díaz-López, A.; Babio, N.; Martínez-González, M.A.; Corella, D.; Amor, A.J.; Fitó, M.; Estruch, R.; Arós, F.; Gómez-Gracia, E.; Fiol, M.; et al. Mediterranean Diet, Retinopathy, Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2015, 38, 2134–2141. [Google Scholar] [CrossRef] [PubMed]
- Huo, R.; Du, T.; Xu, Y.; Xu, W.; Chen, X.; Sun, K.; Yu, X. Effects of Mediterranean-Style Diet on Glycemic Control, Weight Loss and Cardiovascular Risk Factors among Type 2 Diabetes Individuals: A Meta-Analysis. Eur. J. Clin. Nutr. 2015, 69, 1200–1208. [Google Scholar] [CrossRef]
- Sala-Vila, A.; Díaz-López, A.; Valls-Pedret, C.; Cofán, M.; García-Layana, A.; Lamuela-Raventós, R.-M.; Castañer, O.; Zanon-Moreno, V.; Martinez-Gonzalez, M.A.; Toledo, E.; et al. Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial. JAMA Ophthalmol. 2016, 134, 1142–1149. [Google Scholar] [CrossRef]
- Tanaka, S.; Yoshimura, Y.; Kawasaki, R.; Kamada, C.; Tanaka, S.; Horikawa, C.; Ohashi, Y.; Araki, A.; Ito, H.; Akanuma, Y.; et al. Fruit Intake and Incident Diabetic Retinopathy with Type 2 Diabetes. Epidemiology 2013, 24, 204–211. [Google Scholar] [CrossRef]
- Millen, A.E.; Klein, R.; Folsom, A.R.; Stevens, J.; Palta, M.; Mares, J.A. Relation between Intake of Vitamins C and E and Risk of Diabetic Retinopathy in the Atherosclerosis Risk in Communities Study. Am. J. Clin. Nutr. 2004, 79, 865–873. [Google Scholar] [CrossRef] [PubMed]
- Millen, A.E.; Sahli, M.W.; Nie, J.; LaMonte, M.J.; Lutsey, P.L.; Klein, B.E.K.; Mares, J.A.; Meyers, K.J.; Andrews, C.A.; Klein, R. Adequate Vitamin D Status Is Associated with the Reduced Odds of Prevalent Diabetic Retinopathy in African Americans and Caucasians. Cardiovasc. Diabetol. 2016, 15, 128. [Google Scholar] [CrossRef] [PubMed]
- Ross, R.; Neeland, I.J.; Yamashita, S.; Shai, I.; Seidell, J.; Magni, P.; Santos, R.D.; Arsenault, B.; Cuevas, A.; Hu, F.B.; et al. Waist Circumference as a Vital Sign in Clinical Practice: A Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020, 16, 177–189. [Google Scholar] [CrossRef]
- Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clin. Chem. 1972, 18. [Google Scholar] [CrossRef]
- 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022, 45, S175–S184. [CrossRef] [PubMed]
- Wilkinson, C.P.; Ferris, F.L.; Klein, R.E.; Lee, P.P.; Agardh, C.D.; Davis, M.; Dills, D.; Kampik, A.; Pararajasegaram, R.; Verdaguer, J.T. Proposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales. Ophthalmology 2003, 110, 1677–1682. [Google Scholar] [CrossRef]
- Wu, L. Classification of Diabetic Retinopathy and Diabetic Macular Edema. World J. Diabetes 2013, 4, 290. [Google Scholar] [CrossRef]
- Nickels, S.; Schuster, A.K.; Singer, S.; Wild, P.S.; Laubert-Reh, D.; Schulz, A.; Finger, R.P.; Michal, M.; Beutel, M.E.; Münzel, T.; et al. The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25)—Reference Data from the German Population-Based Gutenberg Health Study (GHS). Health Qual. Life Outcomes 2017, 15, 156. [Google Scholar] [CrossRef]
- Mangione, C.M. Development of the 25-List-Item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 2001, 119, 1050. [Google Scholar] [CrossRef]
- Agodi, A.; Barchitta, M.; Valenti, G.; Marzagalli, R.; Frontini, V.; Marchese, A.E. Increase in the Prevalence of the MTHFR 677 TT Polymorphism in Women Born since 1959: Potential Implications for Folate Requirements. Eur. J. Clin. Nutr. 2011, 65, 1302–1308. [Google Scholar] [CrossRef]
- WILLETT, W.; STAMPFER, M.J. TOTAL ENERGY INTAKE: IMPLICATIONS FOR EPIDEMIOLOGIC ANALYSES. Am. J. Epidemiol. 1986, 124, 17–27. [Google Scholar] [CrossRef] [PubMed]
- Trichopoulou, A.; Kouris-Blazos, A.; Wahlqvist, M.L.; Gnardellis, C.; Lagiou, P.; Polychronopoulos, E.; Vassilakou, T.; Lipworth, L.; Trichopoulos, D. Diet and Overall Survival in Elderly People. BMJ 1995, 311, 1457–1460. [Google Scholar] [CrossRef] [PubMed]
- Couto, E.; Boffetta, P.; Lagiou, P.; Ferrari, P.; Buckland, G.; Overvad, K.; Dahm, C.C.; Tjønneland, A.; Olsen, A.; Clavel-Chapelon, F.; et al. Mediterranean Dietary Pattern and Cancer Risk in the EPIC Cohort. Br. J. Cancer 2011, 104, 1493–1499. [Google Scholar] [CrossRef] [PubMed]
- Barchitta, M.; Quattrocchi, A.; Adornetto, V.; Marchese, A.E.; Agodi, A. Tumor Necrosis Factor-Alpha −308 G>A Polymorphism, Adherence to Mediterranean Diet, and Risk of Overweight/Obesity in Young Women. BioMed Res. Int. 2014, 2014, 1–8. [Google Scholar] [CrossRef]
- Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. Diabetes 2015, 64, 631–642. [CrossRef]
- Wang, Q.; Zeng, N.; Tang, H.; Yang, X.; Yao, Q.; Zhang, L.; Zhang, H.; Zhang, Y.; Nie, X.; Liao, X.; et al. Diabetic Retinopathy Risk Prediction in Patients with Type 2 Diabetes Mellitus Using a Nomogram Model. Front. Endocrinol. . 2022, 13. [Google Scholar] [CrossRef]
- Cai, K.; Liu, Y.; Wang, D. Prevalence of Diabetic Retinopathy in Patients with Newly Diagnosed Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes. Metab. Res. Rev. 2022. [Google Scholar] [CrossRef]
- Hammes, H.-P.; Welp, R.; Kempe, H.-P.; Wagner, C.; Siegel, E.; Holl, R.W. Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database. PLoS ONE 2015, 10, e0132492. [Google Scholar] [CrossRef]
- Zhu, W.; Wu, Y.; Meng, Y.-F.; Xing, Q.; Tao, J.-J.; Lu, J. Association of Obesity and Risk of Diabetic Retinopathy in Diabetes Patients. Medicine 2018, 97, e11807. [Google Scholar] [CrossRef]
- Zhou, Y.; Zhang, Y.; Shi, K.; Wang, C. Body Mass Index and Risk of Diabetic Retinopathy. Medicine 2017, 96, e6754. [Google Scholar] [CrossRef]
- Man, R.E.K.; Sabanayagam, C.; Chiang, P.P.-C.; Li, L.-J.; Noonan, J.E.; Wang, J.J.; Wong, T.Y.; Cheung, G.C.-M.; Tan, G.S.W.; Lamoureux, E.L. Differential Association of Generalized and Abdominal Obesity With Diabetic Retinopathy in Asian Patients With Type 2 Diabetes. JAMA Ophthalmol. 2016, 134, 251. [Google Scholar] [CrossRef]
- Klein, R.; Knudtson, M.D.; Lee, K.E.; Gangnon, R.; Klein, B.E.K. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The Twenty-Five-Year Incidence of Macular Edema in Persons with Type 1 Diabetes. Ophthalmology 2009, 116, 497–503. [Google Scholar] [CrossRef]
- Sasso, F.C.; Pafundi, P.C.; Gelso, A.; Bono, V.; Costagliola, C.; Marfella, R.; Sardu, C.; Rinaldi, L.; Galiero, R.; Acierno, C.; et al. High HDL Cholesterol: A Risk Factor for Diabetic Retinopathy? Findings from NO BLIND Study. Diabetes Res. Clin. Pract. 2019, 150, 236–244. [Google Scholar] [CrossRef]
- Madsen, C.M.; Varbo, A.; Nordestgaard, B.G. Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women: Two Prospective Cohort Studies. Eur. Heart J. 2017, 38, 2478–2486. [Google Scholar] [CrossRef]
- Gange, W.S.; Lopez, J.; Xu, B.Y.; Lung, K.; Seabury, S.A.; Toy, B.C. Incidence of Proliferative Diabetic Retinopathy and Other Neovascular Sequelae at 5 Years Following Diagnosis of Type 2 Diabetes. Diabetes Care 2021, 44, 2518–2526. [Google Scholar] [CrossRef] [PubMed]
- Grauslund, J.; Pedersen, F.N.; Andersen, N.; Andresen, J.; Bek, T.; Dinesen, S.; Hajari, J.; Heegaard, S.; Højlund, K.; Laugesen, C.S.; et al. Presence and Development of Diabetic Retinopathy in 153 238 Patients with Type 2 Diabetes in the Danish Registry of Diabetic Retinopathy. Acta Ophthalmol. 2022. [Google Scholar] [CrossRef] [PubMed]
- Yang, N.; Li, M.-X.; Peng, X.-Y. Effects of Intensive Insulin Therapy on the Retinal Microvasculature in Patients with Type 2 Diabetes Mellitus: A Prospective Observational Study. BMC Ophthalmol. 2022, 22, 187. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Ryu, C.; Munie, M.; Noorulla, S.; Rana, S.; Edwards, P.; Gao, H.; Qiao, X. Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients. J. Diabetes Res. 2018, 2018, 1–8. [Google Scholar] [CrossRef]
- Fan, Y.-P.; Wu, C.-T.; Lin, J.-L.; Hsiung, C.A.; Liu, H.Y.; Lai, J.-N.; Yang, C.-C. Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. J. Diabetes Res. 2020, 2020, 1–12. [Google Scholar] [CrossRef]
- Amin, S. V.; Khanna, S.; Parvar, S.P.; Shaw, L.T.; Dao, D.; Hariprasad, S.M.; Skondra, D. Metformin and Retinal Diseases in Preclinical and Clinical Studies: Insights and Review of Literature. Exp. Biol. Med. 2022, 247, 317–329. [Google Scholar] [CrossRef]
- Rossi, G.C.M.; Milano, G.; Tinelli, C. The Italian Version of the 25-Item National Eye Institute Visual Function Questionnaire: Translation, Validity, and Reliability. J. Glaucoma 2003, 12, 213–220. [Google Scholar] [CrossRef]
- Trento, M.; Passera, P.; Trevisan, M.; Schellino, F.; Sitia, E.; Albani, S.; Montanaro, M.; Bandello, F.; Scoccianti, L.; Charrier, L.; et al. Quality of Life, Impaired Vision and Social Role in People with Diabetes: A Multicenter Observational Study. Acta Diabetol. 2013, 50, 873–877. [Google Scholar] [CrossRef]
- Pereira, D.M. Quality of Life in People with Diabetic Retinopathy: Indian Study. J. Clin. Diagn. Res. 2017. [Google Scholar] [CrossRef]
- Martín-Peláez, S.; Fito, M.; Castaner, O. Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. Nutrients 2020, 12, 2236. [Google Scholar] [CrossRef]
- Wong, M.Y.Z.; Man, R.E.K.; Fenwick, E.K.; Gupta, P.; Li, L.-J.; van Dam, R.M.; Chong, M.F.; Lamoureux, E.L. Dietary Intake and Diabetic Retinopathy: A Systematic Review. PLoS ONE 2018, 13, e0186582. [Google Scholar] [CrossRef]
- Jenkins, D.J.A.; Kendall, C.W.C.; Augustin, L.S.A.; Mitchell, S.; Sahye-Pudaruth, S.; Blanco Mejia, S.; Chiavaroli, L.; Mirrahimi, A.; Ireland, C.; Bashyam, B.; et al. Effect of Legumes as Part of a Low Glycemic Index Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus. Arch. Intern. Med. 2012, 172, 1653. [Google Scholar] [CrossRef]
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977–986. [CrossRef]
- Reynolds, A.; Mann, J.; Cummings, J.; Winter, N.; Mete, E.; Te Morenga, L. Carbohydrate Quality and Human Health: A Series of Systematic Reviews and Meta-Analyses. The Lancet 2019, 393, 434–445. [Google Scholar] [CrossRef]
- Mudryj, A.N.; Yu, N.; Aukema, H.M. Nutritional and Health Benefits of Pulses. Appl. Physiol. Nutr. Metab. 2014, 39, 1197–1204. [Google Scholar] [CrossRef]
- Becerra-Tomás, N.; Díaz-López, A.; Rosique-Esteban, N.; Ros, E.; Buil-Cosiales, P.; Corella, D.; Estruch, R.; Fitó, M.; Serra-Majem, L.; Arós, F.; et al. Legume Consumption Is Inversely Associated with Type 2 Diabetes Incidence in Adults: A Prospective Assessment from the PREDIMED Study. Clin. Nutr. 2018, 37, 906–913. [Google Scholar] [CrossRef]


| Male gender, n (%) | 65 (50.4) |
|---|---|
| Age (years) | 70 (65-74) |
| Duration of diabetes (years) | 17 (14-19) |
| BMI (Kg/m2) | 29.8 (26.3-33.8) |
| BMI classification, n (%) | |
| Normal weight | 17 (13.2) |
| Overweight | 54 (41.9) |
| Obese | 58 (45.0) |
| WC (cm) | 105 (98-115) |
| High WC, n (%) | 104 (80.6) |
| HbA1c (%) | 8 (7-8) |
| Fasting plasma glucose (mg/dL) | 133 (121-158) |
| Creatinine (mg/dL) | 1 (1-1) |
| eGFR (mL/min) | 77.5 (58.4-91.4) |
| Microalbuminuria, n (%) | 24 (18.6) |
| Macroalbuminuria, n (%) | 1 (0.8) |
| Cholesterol total (mg/dL) | 164 (143-182) |
| HDL (mg/dL) | 46 (39-53) |
| LDL (mg/dL) | 90 (70-109) |
| Triglycerides (mg/dL) | 117 (89-151) |
| AST (U/L) | 18 (16-23) |
| ALT (U/L) | 19 (14-28) |
| SBP (mmHg) | 130 (120-145) |
| DBP (mmHg) | 75 (70-80) |
| Insulin treatment, n (%) | 54 (41.9) |
| Long-acting insulin analogues | 54 (41.9) |
| Short-acting insulin analogues | 19 (14.7) |
| Other diabetes drugs, n (%) | |
| Metformin | 111 (86) |
| GLP-1 RA | 59 (45.7) |
| SGLT2-I | 31 (24) |
| GLP-1 RA or SGLT2-I | 81 (62.8) |
| DPP4-I | 13 (10.2) |
| Pioglitazone | 17 (13.2) |
| Acarbose | 3 (2.3) |
| Lipid lowering drugs, n (%) | 99 (76.7) |
| Anti-hypertensive drugs, n (%) | 106 (82.2) |
| Anti-platelets drugs, n (%) | 89 (71.2) |
| DR, n (%) | 44 (34.1) |
| NPDR, n (%) | 36 (27.9) |
| PDR, n (%) | 8 (6.2) |
| Chronic kidney disease, % | 75.2 |
| Chronic kidney disease stage, % | |
| Stage 1 | 5 (3.9) |
| Stage 2 | 57 (44.2) |
| Stage 3 | 32 (24.8) |
| Stage 4 | 3 (2.3) |
| Stage 5 | 0 (0.0) |
| Ischemic heart disease | 21 (16.3) |
| Stroke or lower limb revascularization | 10 (7.8) |
| NDR (N=85) |
DR (N=44) |
NPDR (N=36) |
PDR (N=8) |
p (NDR vs. DR) |
p (NDR vs. NPDR vs. PDR) |
p (NPDR vs. PDR) |
|
|---|---|---|---|---|---|---|---|
| Male gender, n (%) | 38 (44.7) | 27 (61.4) | 26 (63.9) | 4 (50.0) | 0.07 | 0.16 | 0.47 |
| Age (years) | 70 (63.5-74) | 70 (65.3-76) | 71 (66-76) | 70 (64-75) | 0.46 | 0.65 | 0.56 |
| Age at diabetes diagnosis (years) | 53 (47-58) | 53 (45-56) | 54 (45-56) | 51 (40-59) | 0.31 | 0.57 | 0.62 |
| Duration of diabetes (years) | 16 (13-19) | 18 (16-21.8) | 18 (15-22) | 18 (17-21) | <0.01 | <0.01 | 0.78 |
| BMI (Kg/m2) | 30 (26.4-34.3) | 28.1 (25.6-32.7) | 27.4 (26-32) | 31.3 (26-39) | 0.12 | 0.09 | 0.17 |
| BMI classification, n (%) | |||||||
| Normal weight | 10 (11.8) | 7 (15.9) | 6 (16.7) | 1 (12.5) | 0.20 | 0.38 | 0.58 |
| Overweight | 32 (37.6) | 22 (50.0) | 19 (52.8) | 3 (37.5) | |||
| Obese | 43 (50.6) | 15 (34.1) | 11 (30.6) | 4 (50) | |||
| WC (cm) | 105 (97-115) | 107 (101-114.8) | 106 (103-112) | 115 (105-125) | 0.53 | 0.29 | 0.13 |
| High WC, n (%) | 69 (81.2) | 35 (79.5) | 28 (77.8) | 7 (87.5) | 0.82 | 0.80 | 0.54 |
| HbA1c (%) | 7 (7-8) | 8 (7-8) | 8 (7-8) | 8 (7-8) | 0.92 | 0.23 | 0.80 |
| Fasting glucose (mg/dL) | 133 (121-156) | 132 (121-161) | 132 (121-161) | 131 (119-171) | 0.67 | 0.91 | 0.96 |
| Creatinine (mg/dL) | 1 (1-1) | 1 (1-1) | 1 (1-1) | 1 (1-1) | 0.70 | 0.83 | 0.08 |
| GFR (mL/min) | 79.8 (61.5-92) | 74.7 (57-87) | 71.4 (56.8-87) | 82.0 (72-96) | 0.41 | 0.34 | 0.27 |
| Microalbuminuria, n (%) | 15 (17.6) | 9 (20.5) | 6 (16.7) | 3 (37.5) | 0.71 | 0.36 | 0.19 |
| Macroalbuminuria, n (%) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | - |
| Cholesterol total (mg/dL) | 162 (141.3-179) | 166 (144-187) | 169 (153-192) | 145 (120-152) | 0.56 | 0.04 | 0.01 |
| HDL (mg/dL) | 45 (38-52.8) | 49 (41-54) | 50 (43-59) | 40 (33-46) | 0.17 | 0.01 | 0.01 |
| LDL (mg/dL) | 87.5 (66.3-109) | 90 (73-108) | 95 (80-112) | 78 (61-84) | 0.95 | 0.16 | 0.03 |
| Triglycerides (mg/dL) | 123 (89-151) | 110 (84.3-163.5) | 107 (84-164) | 127 (80-163) | 0.56 | 0.80 | 0.89 |
| AST (U/L) | 19 (16-24) | 18 (14-21) | 18 (14-21) | 18 (16-21) | 0.16 | 0.37 | 0.96 |
| ALT (U/L) | 20 (14-29) | 17 (14-24) | 17 (13-24) | 21 (16-33) | 0.19 | 0.26 | 0.31 |
| SBP (mmHg) | 130 (123-145) | 133 (120-144) | 133 (125-144) | 128 (120-144) | 0.91 | 0.83 | 0.58 |
| DBP (mmHg) | 75 (70-80) | 70 (66-80) | 70 (66-80) | 70 (66-78) | 0.10 | 0.20 | 0.54 |
| Insulin treatment, n (%) | 29 (34.1) | 23 (52.3) | 17 (47.2) | 6 (75.0) | 0.04 | 0.03 | 0.20 |
| Long-acting insulin analogues | 29 (34.1) | 23 (52.3) | 17 (47.2) | 6 (75.0) | <0.05 | <0.05 | 0.20 |
| Short-acting insulin analogues | 8 (9.4) | 11 (25.0) | 9 (25.0) | 2 (25.0) | 0.02 | 0.06 | 1.00 |
| Pro-Kg insulin daily dose (U) | |||||||
| Long-acting insulin analogues | 0.26 (0.18-0.38) | 0.27 (0.17-0.37) | 0.24 (0.16-0.30) | 0.4 (0.3-0.5) | 0.96 | 0.07 | 0.02 |
| Short-acting insulin analogues | 0.26 (0.17-0.57) | 0.26 (0.21-0.32) | 0.24 (0.18-0.37) | 0.27 (0.26-NA) | 0.60 | 0.76 | 0.73 |
| Total dose | 0.29 (0.20-0.46) | 0.39 (0.22-0.56) | 0.36 (0.24-0.52) | 0.51 (0.34-0.62) | 0.23 | 0.27 | 0.25 |
| Other diabetes drugs, n (%) | |||||||
| Metformin | 78 (91.8) | 33 (75.0) | 26 (72.2) | 7 (87.5) | <0.01 | 0.02 | 0.37 |
| GLP-1 RA | 38 (44.7) | 21 (47.7) | 16 (44.4) | 5 (62.5) | 0.74 | 0.62 | 0.36 |
| SGLT2-I | 16 (18.8) | 15 (34.1) | 13 (36.1) | 2 (25.0) | 0.054 | 0.13 | 0.55 |
| GLP-1 RA or SGLT2-I | 47 (55.3) | 34 (77.3) | 28 (77.8) | 6 (75.0) | 0.01 | <0.05 | 0.87 |
| DPP4-I | 11 (13.4) | 2 (4.5) | 2 (5.6) | 0 (0.0) | 0.13 | 0.28 | 0.50 |
| Pioglitazone | 11 (12.9) | 6 (13.6) | 6 (16.7) | 0 (0.0) | 0.91 | 0.45 | 0.21 |
| Acarbose | 3 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.21 | 0.45 | - |
| Lipid lowering drugs, n (%) | 68 (80.0) | 31 (70.5) | 25 (69.4) | 6 (75.0) | 0.22 | 0.45 | 0.76 |
| Anti-hypertensive drugs, n (%) | 72 (84.7) | 34 (77.3) | 28 (77.8) | 6 (75.0) | 0.30 | 0.57 | 0.87 |
| Anti-platelets drugs, n (%) | 56 (69.1) | 33 (75) | 28 (77.8) | 5 (62.5) | 0.49 | 0.54 | 0.37 |
| NDR (N=85) |
DR (N=44) |
NPDR (N=36) |
PDR (N=8) |
p (NDR vs. DR) |
p (NDR vs. NPDR vs. PDR) |
p (NPDR vs. PDR) |
|
|---|---|---|---|---|---|---|---|
| COMPOSITE SCORE | 99.1 (95.9-99.5) | 99.1 (97-99) | 99.1 (97.6-99.1) | 94.6 (85.7-98) | 0.47 | 0.04 | 0.01 |
| General health | 70.0 (60-77.5) | 65.0 (60.0-77.5) | 65 (60-75) | 72.5 (60-77.5) | 0.63 | 0.92 | 0.96 |
| General vision | 90.0 (70-95) | 87.5 (75-90) | 90 (82.5-90) | 72.5 (55-85) | 0.35 | 0.07 | 0.02 |
| Mental health | 100 (95-100) | 100 (100-100) | 100 (100-100) | 98 (83-100) | 0.17 | 0.01 | 0.07 |
| Ocular pain | 100 (88-100) | 100 (100-100) | 100 (100-100) | 88 (82-100) | 0.16 | <0.01 | 0.02 |
| Near activities | 100 (100-100) | 100 (100-100) | 100 (100-100) | 96 (63-100) | 0.62 | 0.02 | 0.07 |
| Distance activities | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (81-100) | 0.44 | <0.05 | 0.16 |
| Peripheralvision | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (88-100) | 0.69 | 0.17 | 0.40 |
| Social functioning | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (96-100) | 0.77 | 0.10 | 0.33 |
| Color vision | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (100-100) | 0.28 | 0.19 | 0.59 |
| Driving | 100 (100-100) | 100 (100-100) | 100 (100-100) | 96 (67-100) | 0.74 | 0.01 | 0.11 |
| Role difficulties | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (100-100) | 0.15 | 0.14 | 0.60 |
| Dependency | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (100-100) | 0.44 | 0.42 | 0.67 |
| Variable | NDR (N=85) | DR (N=44) | NPDR (N=36) | PDR (N=8) | p (NDR vs DR) | p (NDR vs NPDR vs PDR) | p (NPDR vs PDR) |
|---|---|---|---|---|---|---|---|
| Cereals (g) | 168.3 (113.5-206.6) | 180.8 (136.7-218.5) | 186.7 (141.9-223.5) | 168.9 (126.8-182.1) | 0.19 | 0.21 | 0.26 |
| Vegetables (g) | 345.7 (226.7-478.2) | 331.0 (258.3-416.1) | 331.0 (251.5-424.0) | 329.0 (263.7-361.9) | 0.60 | 0.76 | 0.62 |
| Fruits (g) | 310.0 (193.3-377.3) | 231.2 (191.2-321.2) | 240.5 (193.6-357.6) | 212.3 (187.5-231.9) | 0.15 | 0.15 | 0.23 |
| Meat (g) | 61.3 (48.0-80.0) | 59.5 (48.5-75.0) | 57.2 (48.5-75.0) | 60.7 (56.2-75.5) | 0.94 | 0.96 | 0.71 |
| Dairy products (g) | 278.7 (103.8-331.7) | 269.2 (98.0-329.0) | 208.5 (88.4-329.0) | 315.8 (247.1-333.9) | 0.96 | 0.69 | 0.50 |
| Fish (g) | 53.9 (26.9-86.9) | 51.4 (34.7-74.2) | 51.4 (39.7-66.4) | 41.9 (25.2-86.1) | 0.60 | 0.84 | 0.73 |
| Legumes (g) | 40.3 (16.7-50.6) | 34.0 (21.8-53.1) | 32.2 (23.5-53.6) | 36.7 (27.6-47.7) | 0.03 | 0.08 | 0.33 |
| Ethanol (g) | 0 (0-0.1) | 0.1 (0-0.1) | 0.1 (0-0.1) | 0.1 (0-0.1) | 0.20 | 0.30 | 0.13 |
| Unsaturated/Saturated fat ratio | 2.42 (1.98-2.74) | 2.30 (1.96-2.93) | 2.26 (1.89-2.80) | 2.71 (2.31-2.93) | 0.54 | 0.19 | 0.14 |
| Daily caloric intake (kcal) | 1756.3 (1539.3-1980.0) | 1732.2 (1523.4-2086.4) | 1756.2 (1586.7-2086.4) | 1601.8 (1477.9-1944.7) | 0.60 | 0.60 | 0.43 |
| Carbohydrates (g) | 152.0 (23.1-879.9) | 141.3 (32.1-1147.6) | 128.9 (27.3-1156.5) | 162.3 (60.0-587.4) | 0.81 | 0.65 | 0.46 |
| Fiber (g) | 25.6 (20.1-32.7) | 25.5 (21.4-35.6) | 26.3 (20.5-32.2) | 25.1 (22.1-28.5) | 0.53 | 0.79 | 0.18 |
| Proteins (g) | 82.4 (34.0-824.0) | 82.8 (25.8-871.0) | 45.7 (27.1-876.2) | 91.3 (40.0-162.5) | 0.54 | 0.59 | 0.80 |
| Total fats (g) | 61.4 (22.0-493.5) | 46.9 (21.5-481.4) | 31.3 (18.5-492.9) | 64.2 (24.6-263.4) | 0.65 | 0.71 | 0.03 |
| Saturated fats (g) | 21.0 (16.5-25.3) | 22.8 (17.2-26.1) | 22.7 (17.9-26.0) | 23.2 (15.4-27.9) | 0.25 | 0.51 | 0.96 |
| Monounsaturated Fatty Acids (g) | 36.1 (32.1-44.3) | 37.7 (27.2-56.9) | 37.4 (24.6-56.1) | 56.3 (35.5-60.6) | 0.46 | 0.25 | 0.20 |
| Polyunsaturated fats (g) | 11.3 (9.4-14.1) | 12.0 (9.9-14.9) | 12.0 (9.6-13.8) | 13.4 (10.4-19.4) | 0.30 | 0.25 | 0.19 |
| Iron (mg) | 10.8 (9.2-12.6) | 10.8 (9.7-13.2) | 11.2 (9.8-13.2) | 9.8 (8.4-10.9) | 0.56 | 0.21 | 0.11 |
| Calcium (mg) | 914.9 (722.0-1100.4) | 941.3 (725.9-1244.5) | 966.0 (736.6-1244.5) | 867.8 (630.6-1125.7) | 0.32 | 0.43 | 0.50 |
| Magnesium (mg) | 297.8 (245.5-339.5) | 299.2 (256.0-329.0) | 303.2 (267.2-342.6) | 293.8 (244.5-310.8) | 0.68 | 0.42 | 0.22 |
| Zinc (mg) | 8.6 (6.6-9.6) | 8.6 (7.2-10.5) | 8.7 (8.0-10.5) | 7.5 (6.0-9.1) | 0.41 | 0.25 | 0.15 |
| Vitamin A (mcg) | 891.9 (579.8-1148.3) | 869.9 (687.4-1096.0) | 889.4 (708.3-1113.1) | 728.4 (505.2-834.9) | 0.93 | 0.14 | 0.04 |
| Vitamin B1 (mg) | 1.23 (1.07-1.46) | 1.29 (1.13-1.47) | 1.28 (1.14-1.47) | 1.29 (0.96-1.43) | 0.37 | 0.50 | 0.50 |
| Vitamin B6 (mg) | 1.68 (1.31-1.91) | 1.62 (1.36-1.85) | 1.63 (1.42-1.88) | 1.40 (1.27-1.63) | 0.68 | 0.28 | 0.08 |
| Vitamin C (mg) | 118.5 (82.3-156.8) | 118.7 (87.8-142.6) | 123.1 (100.7-145.9) | 92.3 (79.3-120.7) | 0.88 | 0.63 | 0.27 |
| Vitamin D (mcg) | 5.1 (2.9-8.6) | 5.0 (4.1-7.6) | 5.1 (4.2-7.6) | 4.5 (1.6-5.9) | 0.70 | 0.60 | 0.30 |
| Vitamin E (mg) | 28.5 (25.0-40.1) | 27.3 (21.4-34.2) | 37.2 (30.2-46.6) | 26.8 (20.0-33.4) | 0.45 | 0.51 | 0.04 |
| β-carotene (µg) | 7303.4 (5430.2-9893.6) | 6094.9 (4560.4-8039.8) | 6199.1 (3560.6-7305.6) | 5484.7 (4019.5-7824.5) | 0.54 | 0.45 | 0.19 |
| MDS | 4 (3-5) | 4 (3-5) | 4 (3-5) | 4 (3-5) | 0.66 | 0.52 | 0.63 |
| Model | Comparison | OR (95%CI) | p-value |
|---|---|---|---|
| Model 1 | Legumes (low vs. high consumption) | 2.2 (1.0-4.8) | 0.042 |
| Model 2 | Legumes (low vs. high consumption) | 2.2 (1.0-4.8) | 0.043 |
| Model 3 | Legumes (low vs. high consumption) | 2.5 (1.1-5.8) | 0.037 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).